Multiple Sclerosis Therapeutics Market, By Drug Class (Immunosuppressant, Immunomodulators, Beta Interferons, and Corticosteroids), By Distribution Channel (E-Commerce, Retail Pharmacies, and Hospital Pharmacies), By Mode of Delivery (Oral, Infused/Intravenous, and Injectable), and By Region (EU, NA, APAC, MEA, and LATAM) Analysis, Size, Share, Trends, & Forecast from 2020-2026
REPORT HIGHLIGHT
Multiple sclerosis therapeutics industry was valued at USD 22.38 billion by 2019, growing with 2.5% CAGR during the forecast period, 2020-2026
Multiple sclerosis is a disease of demyelinating disease, in which nerve cells’ insulating covers of the spinal cord and brain get severely damaged. This disease leads in malfunctioning of the nerve systems which in turn causes several symptoms and signs that include psychiatric, mental, and physical issues. Blindness in one eye, double vision, trouble with coordination or sensation, and muscle weakness are some of the other symptoms of multiple sclerosis. The most common symptoms of this disease are slurred speech, prolonged vision loss, complete vision loss, and lack of coordination. Several types of multiple sclerosis include secondary progressive MS (SPMS), primary progressive MS (PPMS), and relapsing-remitting MS (RRMS).
Market Dynamics
Rising demand for new potential drugs and a growing population of people suffering from a secondary progressive and relapsing-remitting multiple sclerosis are some of the major factors driving the growth of the global market. The presence of a robust pipe in the form of drugs such as Zinbryta and Ocrelizumab and their commercialization is further expected to fuel the market growth in the estimated period. Furthermore, early diagnosis of MA disease and growing awareness amongst individuals regarding MA, and advancements in the pharmaceutical industry are predicted to create enormous growth opportunities for prominent players in the market. However, ignoring the symptoms, difficulty in detecting the condition, and improbability in causes of multiple sclerosis are projected to hamper the market growth in the coming years.
Drug Class Takeaway
Based on drug class the market, the global industry is categorized into immunosuppressant (cladribine and others), immunomodulators (glatopa, ponesimod, teriflunomide, copaxone, flingolimod, and others), beta interferons (betaseron and other), and corticosteroids (prednisone and methylprednisolone), and others.
Of these, the immunomodulators segment accounted for the largest market in terms of share in 2019 and is expected to garner the highest revenue during the forecast period. This growth is mainly due to brand loyalty, higher prescription rates, and the existence of a wide range of alternatives for drugs. On the other hand, the immunosuppressant segment is anticipated to experience the highest growth rate by the end of 2026. This growth is attributed to the commercialization of Zinbryta and Ocrelizumab drugs and several advantages of the drugs such as minimal side effects, effectiveness with a low dosage, and high efficacy of the drugs.
Distribution Channel Takeaway
On the basis of the distribution channel, the global industry is categorized into e-commerce, retail pharmacies, and hospital pharmacies. The retail pharmacies market accounted for the largest market share in 2019 and is anticipated to grow at a rapid pace during the forecast period. This growth is majorly due to the improved distribution network of pharmaceuticals giants primarily in the developing economies. On the other hand, the hospital pharmacies segment is estimated to be the second-largest market in terms of revenue by 2026.
Mode of Delivery Takeaway
Based on the mode of delivery, the global industry is bifurcated into oral, infused/intravenous, and injectable drugs. Of these, the oral drugs segment valued at the largest market share in 2019 and is projected to grow rapidly during the forecast period. This growth is majorly due to the introduction of new oral drugs such as Siponimod, Tecfidera, Laquinimod, and Ozanimod. On the other hand, the injectable drugs segment is estimated to witness progressive growth in the projected timeframe owing to its advantages such as high effectiveness with low dosage and advancements in drug development. This is the reason the injectable drugs are gaining popularity in the multiple sclerosis therapeutics market.
Regional Takeaway
On the basis of region, the global industry is divided into North America, Latin America, Asia Pacific, Middle East & Africa, and Europe. The North America region dominated the market in 2019 with revenue and is projected to grow exponentially during the forecast period. The high diagnostic rates and a successive raise in prescription rates have fuelled the market growth in this region.
Along with North America, the Asia Pacific market is estimated to be most profitable by the end of 2026 owing to the presence of unmet needs coupled with the rising infrastructure in this region. The presence of leading manufacturers in this region will also propel the market growth in the Asia Pacific region. The major players are creating opportunities in this region by adopting several strategies such as collaborations and joint ventures with the local manufacturers.
Key Vendors Takeaway
Some of the major key players functioning in the global multiple sclerosis therapeutics market include Biogen Idec, Bayer Healthcare, Teva Pharmaceuticals, Pfizer, Merck, Sanofi-Aventis, and Novartis. These players are focusing on developing novel drugs and mergers & acquisitions to strengthen their company position in the global industry.
For instance, in March 2019, the FDA approved the Mayzent drug developed by Novartis. It is the first-ever approved treatment for the patients with secondary progressive multiple sclerosis (SPMS) for more than a decade. It is used for the treatment of adults with relapsing forms of multiple sclerosis such as clinically isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS), and secondary progressive multiple sclerosis (SPMS).
The market size and forecast for each segment and sub-segments has been considered as below:
- Historical Year – 2015 to 2018
- Base Year – 2019
- Estimated Year – 2020
- Projected Year – 2026
TARGET AUDIENCE
- Traders, Distributors, and Suppliers
- Manufacturers
- Government and Regional Agencies
- Research Organizations
- Consultants
- Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
MULTIPLE SCLEROSIS THERAPEUTICS MARKET PLAYERS
- Biogen Idec
- Bayer Healthcare
- Teva Pharmaceuticals
- Pfizer
- Merck
- Sanofi-Aventis
- Novartis
MULTIPLE SCLEROSIS THERAPEUTICS MARKET, BY DRUG CLASS
- Immunosuppressant
- Cladribine
- Other
- Immunomodulators
- Glatopa
- Ponesimod
- Teriflunomide
- Copaxone
- Flingolimod
- Others
- Beta Interferons
- Betaseron
- Other
- Corticosteroids
- Prednisone
- Methylprednisolone
- Others
MULTIPLE SCLEROSIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
- E-Commerce
- Retail Pharmacies
- Hospital Pharmacies
MULTIPLE SCLEROSIS THERAPEUTICS MARKET, BY MODE OF DELIVERY
- Oral
- Infused/Intravenous
- Injectable
MULTIPLE SCLEROSIS THERAPEUTICS MARKET, BY REGION
- North America
- S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Singapore
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Rest of MEA
TABLE OF CONTENT
1. MULTIPLE SCLEROSIS THREAPEUTICS MARKET OVERVIEW
1.1. Study Scope
1.2. Assumption and Methodology
2. EXECUTIVE SUMMARY
2.1. Market Snippet
2.1.1. Market Snippet by Drug Class
2.1.2. Market Snippet by Distribution Channel
2.1.3. Market Snippet by Mode of Delivery
2.1.4. Market Snippet by Region
2.2. Competitive Insights
3. MULTIPLE SCLEROSIS THREAPEUTICS KEY MARKET TRENDS
3.1. Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Market Opportunities
3.4. Market Future Trends
4. MULTIPLE SCLEROSIS THREAPEUTICS INDUSTRY STUDY
4.1. Porter’s Five Forces Analysis
4.2. Marketing Strategy Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. MULTIPLE SCLEROSIS THREAPEUTICS MARKET LANDSCAPE
5.1. Market Share Analysis
5.2. Key Innovators
5.3. Breakdown Data, by Key manufacturer
5.3.1. Established Player Analysis
5.3.2. Emerging Player Analysis
6. MULTIPLE SCLEROSIS THREAPEUTICS MARKET – BY DRUG CLASS
6.1. Overview
6.1.1. Segment Share Analysis, By Drug Class, 2019 & 2026 (%)
6.2. Immunosuppressant
6.2.1. Overview
6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
6.2.3. Cladribine
6.2.3.1. Overview
6.2.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
6.2.4. Others
6.2.4.1. Overview
6.2.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
6.3. Immunomodulators
6.3.1. Overview
6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
6.3.3. Glatopa
6.3.3.1. Overview
6.3.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
6.3.4. Plonesimod
6.3.4.1. Overview
6.3.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
6.3.5. Teriflunomide
6.3.5.1. Overview
6.3.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
6.3.6. Copaxone
6.3.6.1. Overview
6.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
6.3.7. Flinolimod
6.3.7.1. Overview
6.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
6.3.8. Others
6.3.8.1. Overview
6.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
6.4. Beta Interferons
6.4.1. Overview
6.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
6.4.3. Betaserons
6.4.3.1. Overview
6.4.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
6.4.4. Others
6.4.4.1. Overview
6.4.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
6.5. Corticosteroids
6.5.1. Overview
6.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
6.5.3. Prednisone
6.5.3.1. Overview
6.5.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
6.5.4. Methylprednisolone
6.5.4.1. Overview
6.5.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
6.6. Others
6.6.1. Overview
6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
7. MULTIPLE SCLEROSIS THREAPEUTICS MARKET – BY DISTRIBUTION CHANNEL
7.1. Overview
7.1.1. Segment Share Analysis, By Distribution Channel, 2019 & 2026 (%)
7.2. E-Commerce
7.2.1. Overview
7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
7.3. Retail Pharmacies
7.3.1. Overview
7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
7.4. Hospital Pharmacies
7.4.1. Overview
7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
7.5. Others
7.5.1. Overview
7.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
8. MULTIPLE SCLEROSIS THREAPEUTICS MARKET – BY MODE OF DELIVERY
8.1. Overview
8.1.1. Segment Share Analysis, By Mode of Delivery, 2019 & 2026 (%)
8.2. Oral
8.2.1. Overview
8.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
8.3. Infused/Intravenous
8.3.1. Overview
8.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
8.4. Injectable
8.4.1. Overview
8.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
8.5. Others
8.5.1. Overview
8.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9. MULTIPLE SCLEROSIS THREAPEUTICS MARKET– BY GEOGRAPHY
9.1. Introduction
9.1.1. Segment Share Analysis, By Region, 2019 & 2026 (%)
9.2. North America
9.2.1. Overview
9.2.2. Key Manufacturers in North America
9.2.3. North America Market Size and Forecast, By Country, 2015 – 2026 (US$ Million)
9.2.4. North America Market Size and Forecast, By Drug Class, 2015 – 2026 (US$ Million)
9.2.5. North America Market Size and Forecast, By Distribution Channel, 2015 – 2026 (US$ Million)
9.2.6. North America Market Size and Forecast, By Mode of Delivery, 2015 – 2026 (US$ Million)
9.2.7. U.S.
9.2.7.1. Overview
9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.2.8. Canada
9.2.8.1. Overview
9.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.3. Europe
9.3.1. Overview
9.3.2. Key Manufacturers in Europe
9.3.3. Europe Market Size and Forecast, By Country, 2015 – 2026 (US$ Million)
9.3.4. Europe Market Size and Forecast, By Drug Class, 2015 – 2026 (US$ Million)
9.3.5. Europe Market Size and Forecast, By Distribution Channel, 2015 – 2026 (US$ Million)
9.3.6. Europe Market Size and Forecast, By Mode of Delivery, 2015 – 2026 (US$ Million)
9.3.7. Germany
9.3.7.1. Overview
9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.3.8. Italy
9.3.8.1. Overview
9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.3.9. United Kingdom
9.3.9.1. Overview
9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.3.10. France
9.3.10.1. Overview
9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.3.11. Rest of Europe
9.3.11.1. Overview
9.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.4. Asia Pacific (APAC)
9.4.1. Overview
9.4.2. Key Manufacturers in Asia Pacific
9.4.3. Asia Pacific Market Size and Forecast, By Country, 2015 – 2026 (US$ Million)
9.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2015 – 2026 (US$ Million)
9.4.5. Asia Pacific Market Size and Forecast, By Distribution Channel, 2015 – 2026 (US$ Million)
9.4.6. Asia Pacific Market Size and Forecast, By Mode of Delivery, 2015 – 2026 (US$ Million)
9.4.7. India
9.4.7.1. Overview
9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.4.8. China
9.4.8.1. Overview
9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.4.9. Japan
9.4.9.1. Overview
9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.4.10. South Korea
9.4.10.1. Overview
9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.4.11. Rest of APAC
9.4.11.1. Overview
9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.5. Latin America
9.5.1. Overview
9.5.2. Key Manufacturers in Latin America
9.5.3. Latin America Market Size and Forecast, By Country, 2015 – 2026 (US$ Million)
9.5.4. Latin America Market Size and Forecast, By Drug Class, 2015 – 2026 (US$ Million)
9.5.5. Asia Pacific Market Size and Forecast, By Distribution Channel, 2015 – 2026 (US$ Million)
9.5.6. Latin America Market Size and Forecast, By Mode of Delivery, 2015 – 2026 (US$ Million)
9.5.7. Brazil
9.5.7.1. Overview
9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.5.8. Mexico
9.5.8.1. Overview
9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.5.9. Argentina
9.5.9.1. Overview
9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.5.10. Rest of LATAM
9.5.10.1. Overview
9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.6. Middle East and Africa
9.6.1. Overview
9.6.2. Key Manufacturers in Middle East and Africa
9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2015 – 2026 (US$ Million)
9.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2015 – 2026 (US$ Million)
9.6.5. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2015 – 2026 (US$ Million)
9.6.6. Middle East and Africa Market Size and Forecast, By Mode of Delivery, 2015 – 2026 (US$ Million)
9.6.7. Saudi Arabia
9.6.7.1. Overview
9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
9.6.8. United Arab Emirates
9.6.8.1. Overview
9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)
10. KEY VENDOR ANALYSIS
10.1. Biogen Idec
10.1.1. Company Snapshot
10.1.2. Financial Performance
10.1.3. Product Benchmarking
10.1.4. Strategic Initiatives
10.2. Bayer Healthcare
10.3. Teva Pharmaceuticals
10.4. Pfizer
10.5. Merck
10.6. Sanofi-Aventis
10.7. Novartis
11. 360 DEGREE ANALYSTVIEW
12. APPENDIX
12.1. Research Methodology
12.2. References
12.3. Abbreviations
12.4. Disclaimer
12.5. Contact Us
List of Tables
TABLE List of data sources
TABLE Market drivers; Impact Analysis
TABLE Market restraints; Impact Analysis
TABLE Multiple Sclerosis Threapeutics market: Drug Class Snapshot (2018)
TABLE Segment Dashboard; Definition and Scope, by Drug Class
TABLE Global Multiple Sclerosis Threapeutics market, by Drug Class 2015-2026 (USD Million)
TABLE Multiple Sclerosis Threapeutics market: Distribution Channel Snapshot (2018)
TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
TABLE Global Multiple Sclerosis Threapeutics market, by Distribution Channel 2015-2026 (USD Million)
TABLE Multiple Sclerosis Threapeutics market: Mode of Delivery Snapshot (2018)
TABLE Segment Dashboard; Definition and Scope, by Mode of Delivery
TABLE Global Multiple Sclerosis Threapeutics market, by Mode of Delivery 2015-2026 (USD Million)
TABLE Multiple Sclerosis Threapeutics market: Regional snapshot (2018)
TABLE Segment Dashboard; Definition and Scope, by Region
TABLE Global Multiple Sclerosis Threapeutics market, by Region 2015-2026 (USD Million)
TABLE North America Multiple Sclerosis Threapeutics market, by Country, 2015-2026 (USD Million)
TABLE North America Multiple Sclerosis Threapeutics market, by Drug Class, 2015-2026 (USD Million)
TABLE North America Multiple Sclerosis Threapeutics market, by Distribution Channel, 2015-2026 (USD Million)
TABLE North America Multiple Sclerosis Threapeutics market, by Mode of Delivery, 2015-2026 (USD Million)
TABLE Europe Multiple Sclerosis Threapeutics market, by country, 2015-2026 (USD Million)
TABLE Europe Multiple Sclerosis Threapeutics market, by Drug Class, 2015-2026 (USD Million)
TABLE Europe Multiple Sclerosis Threapeutics market, by Distribution Channel, 2015-2026 (USD Million)
TABLE Europe Multiple Sclerosis Threapeutics market, by Mode of Delivery, 2015-2026 (USD Million)
TABLE Asia Pacific Multiple Sclerosis Threapeutics market, by country, 2015-2026 (USD Million)
TABLE Asia Pacific Multiple Sclerosis Threapeutics market, by Drug Class, 2015-2026 (USD Million)
TABLE Asia Pacific Multiple Sclerosis Threapeutics market, by Distribution Channel, 2015-2026 (USD Million)
TABLE Asia Pacific Multiple Sclerosis Threapeutics market, by Mode of Delivery, 2015-2026 (USD Million)
TABLE Latin America Multiple Sclerosis Threapeutics market, by country, 2015-2026 (USD Million)
TABLE Latin America Multiple Sclerosis Threapeutics market, by Drug Class, 2015-2026 (USD Million)
TABLE Latin America Multiple Sclerosis Threapeutics market, by Distribution Channel, 2015-2026 (USD Million)
TABLE Latin America Multiple Sclerosis Threapeutics market, by Mode of Delivery, 2015-2026 (USD Million)
TABLE Middle East and Africa Multiple Sclerosis Threapeutics market, by country, 2015-2026 (USD Million)
TABLE Middle East and Africa Multiple Sclerosis Threapeutics market, by Drug Class, 2015-2026 (USD Million)
TABLE Middle East and Africa Multiple Sclerosis Threapeutics market, by Distribution Channel, 2015-2026 (USD Million)
TABLE Middle East and Africa Multiple Sclerosis Threapeutics market, by Mode of Delivery, 2015-2026 (USD Million)
List of Figures
FIGURE Multiple Sclerosis Threapeutics market segmentation
FIGURE Market research methodology
FIGURE Value chain analysis
FIGURE Porter’s Five Forces Analysis
FIGURE Market Attractiveness Analysis
FIGURE Competitive Landscape; Key company market share analysis, 2018
FIGURE Drug Class segment market share analysis, 2019 & 2026
FIGURE Drug Class segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Immunosuppressants market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Cladribine market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Others market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Immunomodulators market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Glatopa market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Ponesimod market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Teriflunomide market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Copaxone market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Flingolimod market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Others market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Beta Interferons market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Betaserons market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Others market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Corticosteroids market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Prednisone market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Methylprednidsolone market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Others market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Distribution Channel segment market share analysis, 2019 & 2026
FIGURE Distribution Channel segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE E-Commerce market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Retail Pharmacies market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Hospital Pharmacies market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Mode of Delivery segment market share analysis, 2019 & 2026
FIGURE Mode of Delivery segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Oral market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Infused/Intravenous market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Injectable market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Regional segment market share analysis, 2019 & 2026
FIGURE Regional segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE North America Multiple Sclerosis Threapeutics market share and leading players, 2018
FIGURE Europe Multiple Sclerosis Threapeutics market share and leading players, 2018
FIGURE Asia Pacific Multiple Sclerosis Threapeutics market share and leading players, 2018
FIGURE Latin America Multiple Sclerosis Threapeutics market share and leading players, 2018
FIGURE Middle East and Africa Multiple Sclerosis Threapeutics market share and leading players, 2018
FIGURE North America market share analysis by country, 2018
FIGURE U.S. Multiple Sclerosis Threapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Canada Multiple Sclerosis Threapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Europe Multiple Sclerosis Threapeutics market share analysis by country, 2018
FIGURE Germany Multiple Sclerosis Threapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Spain Multiple Sclerosis Threapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Italy Multiple Sclerosis Threapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE UK Multiple Sclerosis Threapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE France Multiple Sclerosis Threapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Rest of the Europe Multiple Sclerosis Threapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Asia Pacific Multiple Sclerosis Threapeutics market share analysis by country, 2018
FIGURE India Multiple Sclerosis Threapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE China Multiple Sclerosis Threapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Japan Multiple Sclerosis Threapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE South Korea Multiple Sclerosis Threapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Singapore Multiple Sclerosis Threapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Rest of APAC Multiple Sclerosis Threapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Latin America Multiple Sclerosis Threapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Latin America Multiple Sclerosis Threapeutics market share analysis by country, 2018
FIGURE Brazil Multiple Sclerosis Threapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Mexico Multiple Sclerosis Threapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Argentina Multiple Sclerosis Threapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Rest of LATAM Multiple Sclerosis Threapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Middle East and Africa Multiple Sclerosis Threapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE Middle East and Africa Multiple Sclerosis Threapeutics market share analysis by country, 2018
FIGURE Saudi Arabia Multiple Sclerosis Threapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
FIGURE United Arab Emirates Multiple Sclerosis Threapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
